Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Jacobio Pharmaceuticals Group And 2 Other Promising Penny Stocks In Global

In This Article:

Global markets have been experiencing significant volatility due to escalating trade tensions, particularly between the U.S. and China, which has affected investor sentiment and led to fluctuations in major indices. For investors interested in exploring opportunities beyond the mainstream market, penny stocks—though an older term—remain a relevant area of investment that can offer both affordability and growth potential. These stocks typically represent smaller or newer companies, and when backed by strong financials, they may present valuable prospects for those willing to explore less conventional options.

Top 10 Penny Stocks Globally

Name

Share Price

Market Cap

Financial Health Rating

CNMC Goldmine Holdings (Catalist:5TP)

SGD0.425

SGD172.25M

★★★★★☆

Yangzijiang Shipbuilding (Holdings) (SGX:BS6)

SGD2.04

SGD8.04B

★★★★★☆

Angler Gaming (NGM:ANGL)

SEK3.60

SEK269.95M

★★★★★★

SKP Resources Bhd (KLSE:SKPRES)

MYR0.80

MYR1.25B

★★★★★☆

NEXG Berhad (KLSE:NEXG)

MYR0.26

MYR723.36M

★★★★★★

DXN Holdings Bhd (KLSE:DXN)

MYR0.50

MYR2.49B

★★★★★★

Sarawak Plantation Berhad (KLSE:SWKPLNT)

MYR2.26

MYR630.61M

★★★★★★

Lever Style (SEHK:1346)

HK$1.03

HK$643.57M

★★★★★★

Warpaint London (AIM:W7L)

£3.60

£290.83M

★★★★★★

Foresight Group Holdings (LSE:FSG)

£3.41

£386.35M

★★★★★★

Click here to see the full list of 5,651 stocks from our Global Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Jacobio Pharmaceuticals Group

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Jacobio Pharmaceuticals Group Co., Ltd. is an investment holding company focused on the in-house discovery and development of oncology therapies, with a market cap of HK$2.66 billion.

Operations: The company's revenue segment is derived from the research and development of new drugs, amounting to CN¥155.71 million.

Market Cap: HK$2.66B

Jacobio Pharmaceuticals Group, with a market cap of HK$2.66 billion, is focused on oncology therapies but remains pre-revenue. Despite being unprofitable, the company has managed to reduce its losses by 29.6% annually over the past five years and maintains more cash than total debt. Its short-term assets significantly exceed both short- and long-term liabilities, suggesting a solid financial position for covering obligations. The management team and board are experienced, with average tenures of 5.2 and 4.7 years respectively. Recent changes in its Nomination Committee reflect active governance adjustments amidst ongoing business developments.